Benlysta granted Orphan Drug Designation by US FDA as potential Rx of systemic sclerosis, such status facilitates eval i
Tweet Content
Benlysta granted Orphan Drug Designation by US FDA as potential Rx of systemic sclerosis, such status facilitates eval in rare diseases. GSK is planning a trial of belimumab for SSc-associated interstitial lung disease in the first half of 2023 https://t.co/kWItB7NEvn https://t.co/eVbQtKy98H
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off